RxDoctor Payments Data

Khalid Maqsood, MD

Gastroenterology · Clermont, FLNPI 1629047378

Payments from drug & device makers

$7,616in general payments, 2019–2025

Across 468 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$1K
  • Phathom Pharmaceuticals, Inc.$414
  • Takeda Pharmaceuticals U.S.A., Inc.$328
  • Aimmune Therapeutics, Inc.$325
  • Gilead$308
  • plus $2K from 25 others

What the payments were for

  • Consulting fees$290%
  • Food & beverage$7,54499%
  • Education$441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,616 in reported general payments places this provider in the 65th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$299,748
Medicare patients
1,035
Services billed
2,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase63$340,700
RemicadeInfliximab14$85,576
ZenpepLipase/Protease/Amylase16$82,148
LinzessLinaclotide61$58,846
PancreazeLipase/Protease/Amylase14$25,168
VoqueznaVonoprazan Fumarate20$17,403
Mesalamine ErMesalamine17$9,774
PentasaMesalamine12$9,029
Budesonide DrBudesonide14$8,635
Pantoprazole Sodium787$7,956
Dexlansoprazole DrDexlansoprazole21$6,263
Sucralfate96$6,128
Colesevelam Hcl31$5,168
Lubiprostone77$5,126
CholestyramineCholestyramine (With Sugar)68$4,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,937$399,546124 claims
Johnson & JohnsonRemicade$289$85,57614 claims
Aimmune Therapeutics, Inc.Zenpep$325$82,14816 claims
Vivus LLCPancreaze$179$25,16814 claims
Phathom Pharmaceuticals, Inc.Voquezna$414$17,40320 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$328$3,11711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →